Management and outcomes of glioblastoma: 20-year experience in a single Australian institution.
chemotherapy
glioblastoma
radiation therapy
surgery
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
24 Nov 2023
24 Nov 2023
Historique:
received:
26
09
2023
accepted:
09
11
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
aheadofprint
Résumé
We aimed to evaluate the changing patterns in the management of glioblastoma (GBM) and impact on survival outcomes over a 20-year period. This is a retrospective study of patients diagnosed with GBM between 2001 and 2020, who had radiation therapy (RT) in an Australian institution. The primary outcomes were changes in treatment modalities (including surgery, RT, and chemotherapy) over time and overall survival (OS). Multivariable Cox regressions were used to evaluate factors associated with OS, including age, sex, ECOG performance status, treatment modalities, treatment facility, and year of treatment. 1079 patients were included in this study. Thirty-five per cent of patients had gross total resection, increasing from 31% in 2001-2005 to 45% in 2016-2020 (P < 0.001). Sixty-four per cent of patients had ≥60 Gy RT, increasing from 57% in 2001-2005 to 66% in 2016-2020 (P < 0.001). Seventy-five per cent of patients had chemotherapy, increasing from 22% in 2001-2005 to 89% in 2016-2020 (P < 0.001). Treatment received varied based on patients' age and ECOG performance status. The median OS for the entire cohort was 13.0 months (95% CI = 12.0-13.7). Median OS in patients who had maximal treatment (i.e., gross total resection, ≥60 Gy RT and chemotherapy) was 20.6 months (95% CI = 17.3-22.8). In multivariable analyses, age, sex, treatment facility, extent of surgical resection, RT dose, and chemotherapy use were associated with OS. This is one of the largest Australian series on the management and outcomes of GBM spanning a 20-year period. We observed improvement in OS over time, which is likely associated with evolving treatment options over the study period.
Identifiants
pubmed: 37997616
doi: 10.1111/1754-9485.13607
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Journal of Medical Imaging and Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Radiologists.
Références
Australian Institute of Health and Welfare. Cancer in Australia 2021. 2021. Available from URL: https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2021/summary.
Mohile NA, Messersmith H, Gatson NT et al. Therapy for diffuse astrocytic and Oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol 2022; 40: 403-426.
Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5: 1725-1731.
Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583-1588.
Roa W, Kepka L, Kumar N et al. International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2015; 33: 4145-4150.
Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13: 916-926.
Perry JR, Laperriere N, O'Callaghan CJ et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017; 376: 1027-1037.
Dally M, Rosenthal M, Drummond K et al. Radiotherapy management of patients diagnosed with glioma in Victoria (1998-2000): a retrospective cohort study. J Med Imaging Radiat Oncol 2009; 53: 318-324.
Rosenthal MA, Drummond KJ, Dally M et al. Management of glioma in Victoria (1998-2000): retrospective cohort study. Med J Aust 2006; 184: 270-273.
Gan HK, Rosenthal MA, Cher L et al. Management of glioblastoma in Victoria, Australia (2006-2008). J Clin Neurosci 2015; 22: 1462-1466.
Gunjur A, Bressel M, Ryan G. The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. J Med Imaging Radiat Oncol 2012; 56: 567-573.
Harris G, Jayamanne D, Wheeler H et al. Survival outcomes of elderly patients with glioblastoma multiforme in their 75th year or older treated with adjuvant therapy. Int J Radiat Oncol Biol Phys 2017; 98: 802-810.
Jayamanne D, Wheeler H, Cook R et al. Survival improvements with adjuvant therapy in patients with glioblastoma. ANZ J Surg 2018; 88: 196-201.
Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 2005; 11 (19 Pt 1): 6767-6771.
Johnston A, Creighton N, Parkinson J et al. Ongoing improvements in postoperative survival of glioblastoma in the temozolomide era: a population-based data linkage study. Neurooncol Pract 2020; 7: 22-30.
Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.
Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011; 115: 3-8.
Brown TJ, Brennan MC, Li M et al. Association of the Extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol 2016; 2: 1460-1469.
Liu JT, Meza D, Sanai N. Trends in fluorescence image-guided surgery for gliomas. Neurosurgery 2014; 75: 61-71.
Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 707-715.
Almenawer SA, Badhiwala JH, Alhazzani W et al. Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro Oncol 2015; 17: 868-881.
Hau E, Shen H, Clark C, Graham PH, Koh ES, L McDonald K. The evolving roles and controversies of radiotherapy in the treatment of glioblastoma. J Med Radiat Sci 2016; 63: 114-123.
Chen JY, Hovey E, Rosenthal M, Livingstone A, Simes J. Neuro-oncology practices in Australia: a cooperative Group for Neuro-Oncology patterns of care study. Asia Pac J Clin Oncol 2014; 10: 162-167.
Zarnett OJ, Sahgal A, Gosio J et al. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis. JAMA Neurol 2015; 72: 589-596.
Girardi F, Matz M, Stiller C et al. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro Oncol 2023; 25: 580-592.
Yan SS, James ML, Kerstens P, de Lambert M, Robinson BA, Yi M. High-grade glioma - a decade of care in Christchurch. J Med Imaging Radiat Oncol 2019; 63: 665-673.
Halkett GKB, Berg MN, Daudu D et al. Supportive care of patients diagnosed with high grade glioma and their carers in Australia. J Neurooncol 2022; 157: 475-485.
Jones D, Pinkham MB, Wallen MP et al. Benefits of supportive strategies for carers of people with high-grade glioma: a systematic review: strategies for addressing the needs of high-grade glioma carers. Support Care Cancer 2022; 30: 10359-10378.
Cancer Council Victoria and Department of Health Victoria. Optimal care pathway for people with high-grade glioma. 2021.
Bakitas MA, Tosteson TD, Li Z et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 2015; 33: 1438-1445.
Karschnia P, Vogelbaum MA, van den Bent M et al. Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer 2021; 149: 23-33.
Lu VM, Jue TR, McDonald KL, Rovin RA. The survival effect of repeat surgery at glioblastoma recurrence and its trend: a systematic review and meta-analysis. World Neurosurg 2018; 115: 453-459.e3.
Shanker M, Chua B, Bettington C, Foote MC, Pinkham MB. Re-irradiation for recurrent high-grade gliomas: a systematic review and analysis of treatment technique with respect to survival and risk of radionecrosis. Neurooncol Pract 2019; 6: 144-155.
Fazzari FGT, Rose F, Pauls M et al. The current landscape of systemic therapy for recurrent glioblastoma: a systematic review of randomized-controlled trials. Crit Rev Oncol Hematol 2022; 169: 103540.
Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review. JAMA Oncol 2022; 8: 1493-1501.